Member Info for Escapetohome

As far as I can tell cardiogeni now owns a 32,5% stake in Lumen Longevity Clinics, in a share exchange with Kira Health Invest AG. It seems they have secured a funding to be paid in tranches to the tune of $25 million. This will allow them to progress their heart cell medicine CLXR-001.

Following that news Ajan had a top up, so I assume it is a positive.

I recently discovered that Celixir some years ago ran into trouble with the regulator over the conduct of trials. This is no longer relevant now though.

And at this price we all stand to do pretty well if they do, and if they continue to plod along we're ok thanks. There are many many worse.

So sit back and relax folks!

We can always hope. My guess is celea financing will help a little, but like all the other value accretive opportunities, will not enable escape velocity .

You didn't answer what the prefix patent does and why this would give an advantage to enet customers?

Just saying it's great and might bring in some customers is a huge gamble

After Dave's milked the last sheckel out of it.

Selling the next placing , a news update may accompany it.

One of the most disappointing shares in human history.

12k? Very very high.

And the celea funding isn't going to change it much.

The only thing that might bring out some value is a low ball bid.

The bod allow stealing✓

An absolute disaster. Shorts having a whale of a time.

This isn't going anywhere.

Dave's productivity in a full time job was zero, now it's 1\5 of zero.

AI stealth chip? For luring in the green pinkies.

Taking the salary , not producing the value though in the long term.

Take em out at any price, but not before they award themselves further options. Snouts in the trough.

Ajan sold his stake in Roquefort Therapeutics but retains his stake here.

A positive sign , surely?

Good Morning LaGomera

I'm mainly here due to the potential $12 billion market opportunity with 10% CAGR growth. I'm hoping the unique tech can capture a slice of that market.

I'm still trying to understand the April announcement where they formed a partnership with Kira Health Invest AG. Has this arrangement put them on a firmer financial footing?

When I was a shareholder in Celixir they were going to tie up with a company called Ashington Innovations, a SPAC, and a heart valve maker. But this fell through. In the meantime these companies went nowhere. This illustrates the risk here.

I bet they did a darn sight better job in promoting cell bx than Andrew newland.

And it's original incarnation Sula Iron and gold was a pretty poor show, before African battery metals.

A poor history of performance.

That's the price it 'should' be. Whether it will ever get there caused by demand for shares exceeding supply is another matter.

Absolute joke if a management. Save money? The bod can walk.

As someone who has a very small stake in cardiogeni through backing Celixir on crowdfund site, I subsequently had a very small top up, just to keep an interest in the company. I now also have a stake in Coiled Therapeutics as well. I noticed Ajan Reginald sold his stake in Roquefort Therapeutics prior to coil reverse takeover, but keeps his stake here and added a few as well.

How significant is the April announcement on the requirement for funds?

the signing of a conditional share exchange agreement ("SEA") whereby Kira Health Invest AG ("Kira") will purchase 67.5% of the existing share capital of Cell Therapy Limited ("CTL") the wholly-owned operating R&D subsidiary of Cardiogeni (the "Sale Shares"). In consideration for the Sale Shares, CGNI will receive 32.5% of the existing share capital of Lumen Clinics B.V. ("Lumen"), Kira's wholly owned subsidiary which is a leading operator of luxury longevity hotels and wellness clinics with assets in excess €100 million (the "Transaction"), based on the unaudited financial statements for the period to 31 December 2025 ("Unaudited Financial Statements").

The Board has developed its three-year strategy requiring $25 million to gain market approval for CLXR-001.

As part of the Transaction, Kira has agreed, subject to certain conditions, to make available to CTL the amount of up to $25 million (£18.92 million) in loan funding (the "Loan") to execute a pivotal Phase 2b clinical study that could lead to the approval of its heart failure medicine CLXR-001 in the Gulf Cooperation Countries ("GCC").

How significant is the April announcement

The disaster is the poor management who did not manage properly the risk and now have to go cap in hand with their backs to the wall at the worst possible moment. Heads should roll.